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Abstract:   
Background Little is known about the value of long-term follow-up for localised 
cutaneous melanoma from the patients’ perspective. This study aimed to explore the 
benefits and potential downsides of follow-up; feelings about changes to frequency of 
follow-up, and patient-centred recommendations for improving follow-up care. 
Methods Qualitative analysis of 29 in-depth interviews conducted with Australian 
patients undergoing long-term follow-up after surgical treatment of stage I/II melanoma.  
Results Patient-perceived benefits of follow-up included reassurance, early detection of 
new melanomas and non-melanoma skin cancers, education about skin self-
examination, the opportunity to ask questions, and reinforcement of ‘sunsafe’ 
behaviours. Downsides included anxiety leading up to and during follow-up visits; 
inconvenience of travel to attend visits; and lost work time.  Patients varied in their 
engagement with skin-self examination, and their views on multiple skin excisions, but 
highly valued access to specialists for unscheduled visits. Most patients felt their 
follow-up intervals could be extended to 12 months if recommended by their clinician.  
Conclusion The benefits and potential downsides of follow-up should be discussed with 
patients when deciding on a melanoma follow-up plan to achieve a balance between 
inducing additional patient anxiety and providing reassurance.  Follow-up intervals of 
12 months appear to be acceptable to patients.  
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Introduction   
The incidence of cutaneous melanoma in the United Kingdom, the United States and 
Australia has doubled over the last twenty years, 
1-3
 however the mortality rate for 
localised disease remains quite low with five-year relative survival in 2008 reported 
between 92% and 98%.
2,4
 Increased survival and therefore increased prevalence has 
lead to a rapidly growing number of patients in many countries attending post surgical 
follow-up. Clinical practice guidelines in the United Kingdom and the United States 
recommend that patients with American Joint Cancer Committee (AJCC) stage I/II 
melanoma have intensive follow-up at three to six monthly intervals for the first five 
years and then yearly thereafter.
5,6
 In Australia, life-long follow-up is often 
recommended but incurs a substantial commitment of time and effort by both patients 
and physicians.
7
  
 
The main goals of melanoma follow-up are to detect recurrent disease and new 
primaries, to provide psychosocial support, and to systematically collect data to measure 
treatment outcomes.
8,9
 While there is little good evidence to guide the frequency of 
melanoma follow-up, a recent analysis by Turner and colleagues suggests that reduced 
frequency for patients with AJCC stage I or II disease results in only a small difference 
in the number of patients whose diagnosis was delayed by more than two months, while 
substantially reducing the number of lifetime follow-up visits required.
10
  
 
Before any changes are made to reduce the frequency of follow-up, it is important to 
examine the value of follow-up from the patients’ perspective, particularly with respect 
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to the above-mentioned goal of psychosocial support and its role in ongoing melanoma 
‘survivorship’.  Qualitative research methods provide the opportunity to gain an 
understanding of patients’ perceptions and experiences,12 and are particularly suited to 
exploring patient-important goals in cancer care. The aims of this study were to; (1) 
explore patients’ perspectives of the value of follow-up care; including its benefits, 
limitations and potential downsides, (2) examine patients’ thoughts and feelings about 
changes to the frequency of follow-up, and (3) elicit patient-centred recommendations 
for improving follow-up care.  
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Patients and methods 
We conducted semi-structured in-depth interviews with patients undergoing long term 
follow-up after surgical treatment of AJCC stage I/II melanoma. Patients were recruited 
from a single centre, Melanoma Institute Australia.. Participants were selected through a 
purposive sampling strategy to meet the objective of maximum variation of the sample; 
that is to represent both stage I and stage II melanoma;  to include patients across age 
groups;  to represent follow-up care with different physicians;  and to include patients 
with more recent as well as long-term experience of follow-up. Interviews were 
conducted by four female social scientists, not responsible for the patients’ care; either 
face-to-face or over the phone.  The interview guide is summarised in Table 1. 
Participants provided informed consent and the study was approved by the ethics 
committee of Sydney South West Area Health Service, protocol #X09-0364. 
 
All interviews were audio-recorded and transcribed. Framework analysis was conducted 
in two stages following the method outlined by Ritchie.
13
 First, a descriptive framework 
of categories was abstracted from the initial patient interviews by authors RM, LR and 
KM. The framework categorised key themes related to patients’ experiences of follow-
up and reported benefitsand downsides. When all relevant concepts were classified and 
no new issues were being raised in later interviews, further analysis explored the 
explanations given by patients for their thoughts and feelings, and identified 
relationships between the descriptive categories. In addition we specifically searched 
the data on all psychosocial outcomes (cognitive, emotional, social and behavioural) 
proposed by Bossuyt  and McCaffery.
14
 To support data management, analytical 
frameworks were developed in Microsoft Excel.  
6 
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Results 
Thirty patients were interviewed between May and July 2010.  One patient was 
excluded due to subsequent reclassification to stage III disease and thus 29 were 
included in the analysis. Participant characteristics are listed in Table 2. Interviews 
occurred in the patient’s home, workplace or in the Melanoma Institute on a separate 
occasion to the follow-up visit. Six interviews were conducted face to face and 23 by 
telephone. Interviews ranged between 12 minutes and 72 minutes, (mean 30 minutes).  
 
For the study participants, a melanoma follow-up visit consisted of a consultation with a 
physician for medical history and physical examination, (which included the primary 
melanoma site, regional and visceral lymph node fields), with or without a full-body 
skin examination. Diagnostic imaging and skin photography was conducted for some 
patients at the physicians’ discretion.  
 
We describe the study findings below under the following headings: patient-perceived 
benefits and downsides of follow-up; views about frequency of follow-up and risk 
perception; views about multiple excisions; involvement in skin self-examination; and 
patient-centred recommendations for follow-up care. The benefits and downsides of 
follow-up are summarised in Table 3 and illustrative quotations are included in Table 4.. 
 
Perceived benefits of follow-up 
Reassurance 
The overwhelming benefit to patients was the reassurance they gained from seeing a 
competent skin specialist whose findings they could trust. This feeling of reassurance 
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was related to several factors. First, the confirmation of no new melanomas, as patients’ 
main concerns were related to a fear about further disease and they primarily sought 
confirmation of their hope that they remained disease free.  Comprehensive skin checks 
especially in anatomical locations the patient could not see (such as their back, neck and 
soles of feet) added to this  reassurance..  
 
Second, patients were reassured by the experience of the Melanoma Institute physicians, 
in particular the reputation of the surgeons and the tertiary referral hospitals. This 
reassurance was related to the physicians’ ability to give definitive answers regarding 
suspicious lesions, as well as the prompt and appropriate treatment of a suspected new 
melanoma or recurrence. Third, patients felt reassured by continuity of their follow-up 
care, particularly when the surgeon who initially treated them provided ongoing follow-
up. Patients described feelings of comfort, confidence and security, of being listened to 
and of being looked after.   
 
 
Early detection and treatment of other skin cancers 
Some patients felt the benefit of follow-up was the earlier detection of a new primary 
melanoma that was still thin, or had not become too ‘advanced’. (Table 4) Many 
patients agreed that an additional benefit of regular follow-up was the treatment of other 
non-melanoma skin cancers, . particularly the convenience of having them removed  in 
a single follow-up visit, at the same time as their melanoma skin check.  
 
Education 
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Gaining knowledge about the diagnosis of melanoma and an explanation of the degrees 
of severity was another perceived benefit of follow-up. Patients valued the opportunity 
to learn about their ongoing prognosis and the changing risk of recurrence over time. 
(Table 4) 
 
Patients also described the benefits of learning about broader topics in melanoma care 
such as the patterns of genetic inheritance for melanoma, new melanoma treatments 
such as B-RAF kinase inhibitors, as well as opportunities to participate in research 
studies. In contrast to the majority of participants who valued follow-up as a source of 
expanding their knowledge and understanding of melanoma, two patients said they did 
not want to know anything else about melanoma because talking about the topic was a 
source of anxiety. 
  
Opportunity to ask questions  
A consistently reported benefit of follow-up was the opportunity to ask questions of a 
melanoma specialist. These included questions about the signs or symptoms patients 
had experienced in the interval between follow-up visits; individual moles or changes to 
their skin; the risk of melanoma to their family members; whether there was a need for 
further investigations (i.e. diagnostic imaging); and questions related to prevention, such 
as ‘how effective are sunscreens?’ Patients valued expert opinion, and would often store 
up a number of questions for each follow-up visit.  
 
Health promotion - sun safe behaviour (self and family) 
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Patients valued follow-up for its reinforcement of sun safe behaviours and appreciated 
education about sun protection as an ongoing reminder to themselves and their family. 
For example encouraging the use of hats, long sleeved shirts and broad spectrum 
sunscreens, and covering up when outdoors. As a result of these reinforced messages 
many patients talked about changes to their behaviour to minimise sun exposure. 
 
Perceived downsides of follow-up 
Anxiety  
Anxiety associated with follow-up visits was an important concern which was 
experienced by a large proportion of the study participants. Symptoms of this anxiety 
included insomnia, teeth clenching, apprehension, paranoia, feelings of nervousness and 
tension, unease, feelings of dread when passing the hospital and ruminating about the 
worst-case scenario. Patients reported that these symptoms started from one week prior 
to the visit to approximately one hour beforehand.  However all participants stated that 
they felt relieved once the visit was over, especially when a ‘melanoma-free’ diagnosis 
was given.  Patients identified a number of different factors as the source of their 
anxiety. Some were anxious about being told of a recurrent or new melanoma; 
particularly if they had friends or family members who had died of melanoma (or other 
cancers), and follow-up visits served to remind them of the severity of the disease. 
Others were anxious about their follow-up due to a prior bad experience with their 
initial diagnosis, such as a suspicious lesion that was dismissed as benign. Patients also 
reported feeling worried and fearful of cancer spreading in their body, and again 
attending follow-up brought these thoughts to the forefront of their mind.  
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Inconvenience of travel and lost work opportunity 
The distance required to travel to the Melanoma Institute was commonly identified as a 
downside for attending regular follow-up. Some patients travelled many hours to get to 
the Institute, but on the whole nearly all patients felt the travel and inconvenience was 
worth it for the specialist care received. Several patients had tried follow-up at a local 
skin cancer clinic closer to home and many had returned to the Melanoma Institute, or 
chosen to alternate their follow-up care with a local primary care physician. Some 
patients reported that a melanoma follow-up visit meant a full day of work was lost 
which made it expensive, particularly for those in casual employment who were not 
eligible for paid sick-leave. 
 
Frequency of follow-up and risk perception 
The frequency of recommended follow-up often signalled the level of risk (disease 
severity) to patients. When the follow-up interval was extended from four to six months, 
or from six to 12 months, this was generally viewed by patients as a marker of good 
health. Similarly if the frequency was reduced from 12 monthly back to 6 monthly this 
was often seen to signal an increased risk of recurrence or a new primary. Across the 
sample, there was complete trust in the physicians’ recommendation about frequency of 
follow-up, with most patients saying they would accept an increase or decrease as 
recommended. This was based on the belief that intervals would not be extended unless 
it was safe to do so. Some patients however said they would be reluctant to extend their 
intervals beyond 12 months. This was related to past experiences of having to make 
unscheduled visits for new lesions that appeared between follow-up visits, or a fear that 
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a new melanoma could grow fast enough to kill if left undetected for more than 12 
months.  
 
Views about multiple excisions 
Excision of multiple skin lesions was perceived by patients as either a positive or 
negative practice, depending on the patient’s interpretation of  why it was being done, or 
whether they valued a ‘conservative’ versus  ‘better safe than sorry’ approach to care. 
For example, multiple excisions were perceived as a positive practice by those who 
preferred early excision and removal of any potentially malignant lesion as quickly as 
possible. For other patients multiple excisions indicated a physician’s lack of 
confidence in being able to conduct accurate lesion assessment and diagnosis. Many 
patients expressed concern about the multiple excisions that had been performed at skin 
cancer clinics and questioned whether the doctors involved might have been motivated 
by a financial incentive.   
 
Involvement in skin self-examination  
Patients varied in their engagement with skin self -examination between follow-up 
visits.  Our sample included some patients (and partners) who were very involved in 
checking their skin every month. These patients reported that the early detection of 
melanomas was a shared responsibility between themselves and their doctor. Others 
were not engaged in self-examination at all and preferred to completely transfer the 
responsibility for skin checks to the Melanoma Institute physicians. 
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Recommendations for follow-up care 
While most patients were pleased with the follow-up care they received, there were a 
number of suggestions to make the follow-up more patient-centred. To support their 
psychological and emotional needs patients suggested longer consultations with their 
surgeon at the time of initial diagnosis. As follow-up progressed over the longer term 
some patients felt that other health practitioners such as specialist nurses could support 
these needs. In addition, peer support programs during follow-up were suggested to help 
come to terms with being a melanoma survivor. In terms of improvements to the follow-
up service, patients suggested a reminder system for scheduled visits and an on-site 
outlet or shop for purchasing sun protective clothing.  
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Discussion 
This study raises several new findings with implications for melanoma practice related 
to how patients may interpret key aspects of follow-up care. First, the benefits and 
potential downsides of follow-up should be discussed with patients when deciding on a 
cancer follow-up plan, as a balance is required between inducing additional patient 
anxiety and providing much wanted reassurance.  It may be helpful for physicians to 
inform new patients that others find follow-up visits anxiety provoking, but this is 
mostly outweighed by the reassurance gained. 
 
Second, the frequency of follow-up signals a specific level of risk to patients.  This 
suggests the importance of discussing with patients the correlation between frequency 
of follow-up and risk, and the basis for any changes in frequency of visits. It may also 
be important to differentiate between changes made to the schedule of an individual 
patient, e.g. due to developments in their personal risk profile, and more general 
changes recommended in follow-up guidelines. Most patients would be likely to accept 
follow-up intervals of 12 months if it was recommended by their physician; however 
they would need assurance that they could make an unscheduled visit at short notice if 
required.  Third, because multiple excisions were viewed both positively and negatively 
by patients, it may be important for physicians to discuss their approach to suspicious 
lesions and explore how that corresponds with the patients’ own preferences. For 
example, clarifying whether patients prefer to have lesions biopsied and removed 
immediately, or alternatively, observed with a careful watch and wait approach.   
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Finally, there are implications arising from the apparent variation in patients’ 
engagement with skin self-examination.  Although a majority of recurrences or new 
melanomas are reported to be self-detected,
15
 patients who are reluctant or unable to 
engage in skin self-examination may require more frequent follow-up visits than those 
who take an active role in monitoring their own skin. Patients who are willing to share 
the responsibility of skin surveillance, and feel competent in their ability to check for 
recurrences and new primaries, may be more likely to find a suspicious lesion and 
return earlier for an unscheduled visit with their doctor.  These patients may find less 
frequent follow-up acceptable and their physicians may also feel confident in seeing less 
often those patients who are fully engaged in self-examination. It is not clear, however, 
if they are any better at assessing skin lesions than those not engaged in regular self-
examination. A training program for motivated patients and their partners could  
improve the level of self-detection.
16
  
 
This study confirms findings from our previous systematic review of patients’ 
perspectives on melanoma follow-up, that anxiety is common, but that patients highly 
value the reassurance, information and psychosocial support they receive during follow-
up.
11
 The patients participating in our study were knowledgeable about melanoma 
follow-up and satisfied with their care.  This differed substantially from the findings of 
a study of survivors of other tumour types who said they did not know what to expect 
after active treatment was completed and felt they did not receive adequate follow-up.
18
 
 
If the frequency of scheduled follow-up visits for patients with stage I/II melanoma was 
reduced then our study suggests the following may need to occur to meet the 
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psychosocial needs of patients in other ways. (1) A longer consultation following 
surgical treatment that focuses on the aims and frequency of the follow-up schedule. (2) 
A clear process for unscheduled visits should the patient and/or their primary care 
physician be concerned about new disease. (3) A skin self-examination training program 
for patients and their partners that discusses signs and symptoms of melanoma, and 
outlines the recommended frequency of skin self-examination.   
 
Limitations 
Patients in our study sample were all actively attending follow-up at the Melanoma 
Institute Australia. Even though some may have missed one or two scheduled visits in 
the past, they did not represent patients who choose not to participate in follow-up at all, 
or who may attend local physicians only.  Our findings may thus only be transferable to 
the type of patients who adhere to follow-up schedules in specialist centres.  
 
Further research subsequent to this study could include surgeons’ perspectives of 
melanoma follow-up and the perceived impact of a reduced frequency of follow-up on 
long term care. Further research related to interventions to improve psychosocial care in 
melanoma follow-up could be examined. We note that a randomised controlled trial of 
less frequent follow-up for patients with stage I/II melanoma patients is underway in the 
Netherlands.
19
 with the primary end-point a composite measure of patients’ well-being, 
(expressed in health related quality of life, level of anxiety and satisfaction with the 
follow-up schedule). 
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Conclusions 
The benefits and potential downsides of follow-up should be discussed with patients 
when deciding on a melanoma follow-up plan, as there is a delicate balance between 
inducing patient anxiety and providing much wanted reassurance.  Patients could 
benefit from knowing the rationale for excision of new lesions and the implications of 
any changes to follow-up schedules. Our study suggests intervals between follow-up 
visits could be extended to 12 months if patients were confident that they could access a 
melanoma specialist at short notice.  
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Table  1. Summary of semi-structured interview guide
*
 
 
Experiences of follow-up: positive and negative 
1. Tell me a bit about what it is like to come for the follow-up appointments?   
2. What are the main things that you get from coming for regular follow-ups?   
3. Do you also attend for regular skin checks anywhere else other than the 
melanoma unit?  
4. How do you usually feel about coming to see the doctor?  
5. Would you say there are any (other) good things or downsides about coming for 
regular follow up appointments?  
 
Personnel conducting follow-up 
1. How important is it to you what type of health professional does your ongoing 
skin checks in the future?   
 
Intervals between appointments  
1. What about the length of time between appointments – does the gap between 
visits suit you?    
2. Have you ever found any suspicious moles or changes in your skin between 
appointments? 
3. Have you ever missed or rescheduled a follow-up appointment?  
 
Information and other needs  
1. What has been the most useful source of information about melanoma?  
2. Is there anything else that you would like to see added to the follow-up or 
monitoring process?  
 
*
Full interview schedule available from authors
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Table 2 – Patient characteristics (n=29) 
Characteristic  n % 
Age group (years) 20-29 1 3 
 30-39 1 3 
 40-49 2 7 
 50-59 9 31 
 60-69 11 38 
 70-79 1 3 
 ≥ 80 4 14 
    
Sex Male 17 59 
 Female 12 41 
    
Highest education level Degree or higher 11 38 
 Diploma or certificate 7 24 
 Completed high school (Yr 12) 3 10 
 Completed intermediate school (Yr 10) 7 24 
 Unknown  1 3 
    
Employment status Employed full time 11 38 
 Employed part time 5 17 
 Retired 13 45 
    
Breslow thickness (mm) ≤1.0 10 34 
 1.01-2.0 13 45 
 2.01-4.0 5 17 
 >4.0 1 3 
    
AJCC* stage of disease Stage I 19 66 
 Stage II 11 38 
    
Histological type Superficial spreading melanoma 13 45 
 Nodular  melanoma 4 14 
 Lentigo maligna melanoma 2 7 
 Not classified 10 34 
    
Anatomical location Head/neck 6 21 
 Trunk  8 27 
 Limbs 15 52 
    
Number of primary melanomas 1 23 79 
 > 1 6 21 
    
Time since diagnosis of first primary melanoma 0-12 months 1 3 
 1-2 years 3 10 
 2-5 years 9 31 
 > 5 years  16 55 
    
Follow-up clinician Surgeon 11 38 
 Dermatologist 1 3 
 Melanoma unit general physician 17 59 
    
Distance from home to melanoma unit in km  
median (range) 
 39 
 
(8-609) 
*AJCC = American Joint Cancer Committee 
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Table 3. Summary of patient-perceived benefits and downsides of melanoma follow-up  
Benefits  Downsides 
 Reassurance of being checked by a skilled specialist  Anxiety leading up to and during the follow-up visit 
 Early detection of new melanomas   Inconvenience of travel to attend visits 
 Treatment of other skin cancers, such as BCCs,* SCCs*  Lost work time related to follow-up visits 
 Education of melanoma aetiology, diagnosis, treatments, skin self-
examination  
 Undressing for full body skin examinations 
 Opportunity to ask questions of specialists  
 Health promotion - sun safe behaviour (for self and family)  
*
Basal cell carcinomas, Squamous cell carcinomas 
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Table 4. Examples of participant quotations that illustrate the main findings of the study 
Main finding Sample participant quotation 
Perceived benefits of follow-up 
(Reassurance) 
"He checks everything…he checks between my toes, he checks through my hair 
thoroughly; he always checks the lymph glands under the arms and in the groin…I 
always feel when I come out of there that it’s my best chance of being told there’s 
nothing there at the moment." (woman, 50-59 years) 
Perceived benefits of follow-up  
(Early detection)  
“I'm hoping that if anything new is starting they'll pick it up before it gets bad...I 
guess that's the benefit of going isn't it?  You can catch them early." (man, 50-59 
years) 
Perceived benefits of follow-up  
(Education)  
"… the professor explained that it’s, that it’s like a parabola…in the first 6 months 
after you’ve done the operation the chances of reoccurring are reasonably high...and 
each 6 months that drops down lower until it gets along to the 5% mark..." (man, > 
80 years) 
Perceived downsides of follow-up  
(Anxiety) 
"… there is this lurking feeling in the back in your mind that a melanoma is going to 
jump up and get you somewhere or it could be a secondary somewhere else that they 
didn’t – that it got away at some stage.” (man, 60-69 years) 
Frequency of follow-up "When they told me to come now at 12 months intervals I did not get anxious about that, I 
took that advice and I took it as good news.” (man, 60-69 years) 
Views about multiple excisions “...those cancer clinics, you know, the doctors are just there to make the dough, they want to 
cut everything out of everyone because they get more money.” (man, 60-69 years) 
 
